ProMIS Neurosciences Inc. Common Shares (ON) financials
$10.64−0.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$40.2M | -$16.8M | -$14.3M | -$23.4M |
| Net income | -$39.7M | $2.8M | -$13.2M | -$18.1M |
| Net margin | — | — | — | — |
| Diluted EPS | $-22.61 | $2.63 | $-26.75 | $-60.25 |
| EBITDA | -$40.2M | -$16.8M | -$14.2M | -$23.4M |
| Operating cash flow | -$28.1M | -$27.2M | -$10.8M | -$17.0M |
| Free cash flow | -$28.1M | -$27.2M | -$10.8M | -$17.0M |
| Diluted shares | 1.8M | 1.1M | 0.5M | 0.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $6.1M | $13.3M | $12.6M | $5.9M |
| Short-term investments | $33.8K | $33.1K | $32.4K | $31.0K |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $9.2M | $18.9M | $13.6M | $6.9M |
| Total liabilities | $10.4M | $2.4M | $9.4M | $8.3M |
| Shareholders' equity | -$1.3M | $16.5M | $4.2M | -$1.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology